Carvotroline

Carvotroline (INNTooltip International Nonproprietary Name; developmental code name WY-47791) is a dopamine D₂ receptor antagonist and serotonin 5-HT_2A receptor antagonist which was under development as a potential antipsychotic but was never marketed.^[1][2][3][4] It showed modest or moderate affinity for the dopamine D₂ and serotonin 5-HT₂ receptors and produced antipsychotic-like effects in animals.^[5][3][4] The drug was being developed by Wyeth.^[1] It reached phase 1 clinical trials prior to the discontinuation of its development.^[1][6] Carvotroline was first described in the scientific literature by 1991.^[7]

Other namesWY-47791; WY47791; Wy-47791

Routes of
administrationUnknown^[1]

Drug classDopamine D₂ receptor antagonist; Serotonin 5-HT_2A receptor antagonist

ATC code

• None

Quick facts Clinical data, Other names ...

Carvotroline

Clinical data
Other names	WY-47791; WY47791; Wy-47791
Routes of administration	Unknown[1]
Drug class	Dopamine D2 receptor antagonist; Serotonin 5-HT2A receptor antagonist
ATC code	None
Identifiers
IUPAC name 8-fluoro-2-(2-pyridin-4-ylethyl)-1,3,4,5-tetrahydropyrido[4,3-b]indole
CAS Number	107266-08-0
PubChem CID	72038
DrugBank	DB19640
ChemSpider	65031
UNII	1Q63WWP8G5
ChEMBL	ChEMBL300443
CompTox Dashboard (EPA)	DTXSID10147990
Chemical and physical data
Formula	C18H18FN3
Molar mass	295.361 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN(CC2=C1NC3=C2C=C(C=C3)F)CCC4=CC=NC=C4
InChI InChI=1S/C18H18FN3/c19-14-1-2-17-15(11-14)16-12-22(10-6-18(16)21-17)9-5-13-3-7-20-8-4-13/h1-4,7-8,11,21H,5-6,9-10,12H2 Key:PMXOASNGMJAYTN-UHFFFAOYSA-N

Close